KDR and hepatocellular carcinoma: It is indeed interesting to note that sorafenib is the only FDA approved anti-angiogenic agent for hepatocellular carcinoma (HCC) and the only TKI (in the list of inhibitors in clinical trials for HCC) that targets two distinct nodes of the VEGF/VEGFR2 pathway [72].